课题基金 / 基金详情

ENDOZEPINE 4--A NATURAL BENZODIAZEPINE RECEPTOR LIGAND

ENDOZEPINE 4--A NATURAL BENZODIAZEPINE RECEPTOR LIGAND
内氮卓4--天然苯二氮卓受体配体
批准号:
2332998
负责人:
Jeffrey D Rothstein
金额:
$21.94万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1995
资助国家:
美国
项目状态:
已结题
起止时间:
1995-04-01 至 1998-01-31

项目摘要

项目成果

Jeffrey D Rothstein的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Endozepine-4 is a newly identified natural chemical that is active at the benzodiazepine receptor (endozepine), and is neither a benzodiazepine nor a peptide. It is a low molecular weight molecule that has a high affinity for the benzodiazepine binding site of the GABAA receptor and is present in pharmacologically relevant concentrations in human and rat brain. It acts selectively at the benzodiazepine receptor. Like the benzodiazepine receptor agonist, diazepam, it can potentiate GABA-mediated chloride fluxes, and can serve as an anticonvulsant. Furthermore, preliminary studies provide evidence that endozepine-4 can cause encephalopathy, and may be the cause of idiopathic recurring stupor and may contribute to hepatic encephalopathy. The proposed studies will examine the role of endozepine-4 in the pathogenesis of idiopathic recurring stupor and hepatic encephalopathy. An animal model will be used to investigate how human and rat endozepine-4 causes encephalopathy and whether these actions occur via the benzodiazepine receptor. (l) We will identify alterations in endozepine-4 in patients with idiopathic recurring stupor and hepatic encephalopathy and determine whether these changes correlate with the clinical level or temporal course of encephalopathy. Significance: Studying endozepine-4 in serum and CSF from patients with these disorders will serve to define its role in idiopathic recurring stupor and hepatic encephalopathy. (2) We propose to test the hypothesis that alterations of endozepine-4 exist in animal models of hepatic encephalopathy and that excess endozepine-4 can cause encephalopathy and therefore contribute to the disease. Significance: Animal models of excess endozepine-4 and animal encephalopathy models will allow us to directly test the hypothesis that endozepine-4 can cause or contribute to encephalopathy. (3) We will test the hypothesis that the behavioral actions of endozepine- 4 are mediated via benzodiazepine receptors by examining its anti-anxiety and anti-convulsant properties. Significance: These studies will determine if naturally occurring endozepine-4 has the functional properties of other synthetic benzodiazepine agonists - anxiolytic and/or anticonvulsant. It is anticipated that the results of these experiments should provide important information on a new neuromodulator that may be an important cause or contributor to certain encephalopathic diseases. Endozepine-4 may also be an important allosteric regulator of GABAergic networks in the nervous system. In addition, the possibility that it could serve as a new class of "natural" anticonvulsants adds additional impetus for its study.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Nuclear and Glial Dysfunction in Neurodegeneration
  • 批准号:
    10664230
  • 项目类别:
  • 资助金额:
    $122.81万
  • 财政年份:
    2023
  • 负责人:
    Jeffrey D Rothstein
  • 依托单位:
Astrocyte Norrin, Norrie disease and Neurodegeneration
  • 批准号:
    10383676
  • 项目类别:
  • 资助金额:
    $44.24万
  • 财政年份:
    2019
  • 负责人:
    Jeffrey D Rothstein
  • 依托单位:
ALS/FTD mutant C9orf72-induced genetic and nuclear pathology in iPS cell models
  • 批准号:
    8613778
  • 项目类别:
  • 资助金额:
    $35.44万
  • 财政年份:
    2013
  • 负责人:
    Jeffrey D Rothstein
  • 依托单位:
ALS/FTD mutant C9orf72-induced genetic and nuclear pathology in iPS cell models
  • 批准号:
    8913279
  • 项目类别:
  • 资助金额:
    $35.44万
  • 财政年份:
    2013
  • 负责人:
    Jeffrey D Rothstein
  • 依托单位:
海外基金